Study Summary
This trial tests a potential new vaccine against dengue in healthy people aged 18-59; 11 visits over 7 months. Blood, urine tests & survey; optional lymph node aspiration & 12mo follow-up.
- Dengue Fever
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 3 Secondary · Reporting Duration: Days 3, 6, 9, 12 and 15
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Primary Heterotypic DENV Antibody Profile
1 of 3
Flavivirus Naive
1 of 3
Polytypic DENV Antibody Profile
1 of 3
Experimental Treatment
200 Total Participants · 3 Treatment Groups
Primary Treatment: Primary Heterotypic DENV Antibody Profile · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 59 · All Participants · 16 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this experiment open to octogenarians?
"The necessary qualifications for participants of this trial are those aged between 18 and 59. For minors, there are 13 clinical trials available, while seniors can look towards 12 options." - Anonymous Online Contributor
How can individuals assess the potential risks of Flavivirus Naive?
"While there is limited data backing both safety and efficacy, due to the nature of this Phase 1 trial, our team at Power has rated Flavivirus Naive's security a score of 1." - Anonymous Online Contributor
Are there still open slots for enrollment in this experiment?
"As per the data available on clinicaltrials.gov, this particular trial is no longer accepting candidates for participation; it was initially posted to the website in late January of 2023 and saw its last update a week prior. Nevertheless, there are 26 other trials that remain open to enrollment at present time." - Anonymous Online Contributor
Is my eligibility sufficient to participate in this experiment?
"This trial is seeking two hundred individuals who have already been exposed to dengue, aged 18-59 years old. Furthermore, participants must be in good health and agree to forgo any other vaccines or travel to an endemic area throughout the study's duration. They also must commit to using a highly effective form of contraception if applicable and provide informed consent before taking part. Additionally, their absolute neutrophil count (ANC) should exceed 750 cells/microliter and creatinine levels should remain below 1.5 mg/dL." - Anonymous Online Contributor